850 related articles for article (PubMed ID: 27699721)
21. Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial.
Lim YS; Lee YS; Gwak GY; Byun KS; Kim YJ; Choi J; An J; Lee HC; Yoo BC; Kwon SY
Hepatology; 2017 Sep; 66(3):772-783. PubMed ID: 28370419
[TBL] [Abstract][Full Text] [Related]
22. Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy.
Chaung KT; O'Brien C; Ha NB; Nguyen NH; Trinh HN; Nguyen MH
J Clin Gastroenterol; 2016 Apr; 50(4):338-44. PubMed ID: 26646801
[TBL] [Abstract][Full Text] [Related]
23. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
Lavocat F; Dény P; Pichoud C; Al Hawajri N; Kitrinos K; Borroto-Esoda K; Zoulim F
J Hepatol; 2013 Oct; 59(4):684-95. PubMed ID: 23742912
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.
Ze E; Baek EK; Lee JJ; Chung HW; Ahn DG; Cho HJ; Kwon JC; Kim HJ; Lee H
Clin Mol Hepatol; 2014 Sep; 20(3):267-73. PubMed ID: 25320730
[TBL] [Abstract][Full Text] [Related]
25. Compare with safety and efficacy of entecavir and adefovir dipivoxil combination therapy and tenofovir disoproxil fumarate monotherapy for chronic hepatitis B patient with adefovir-resistant.
Lai MC; Lian JS; Zhang WJ; Xu J; Zhou L; Zheng SS
Math Biosci Eng; 2019 Oct; 17(1):627-635. PubMed ID: 31731368
[No Abstract] [Full Text] [Related]
26. Efficacy of entecavir-based rescue therapy in lamivudine-resistant chronic hepatitis B patients in China: a retrospective study.
Li W; Wang L; Liu Y; Li Y; Yu S
Pharmazie; 2018 Apr; 73(4):223-247. PubMed ID: 29609690
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination.
Park JH; Jung SW; Park NH; Park BR; Kim MH; Kim CJ; Lee BU; Jeong ID; Kim BG; Bang SJ; Shin JW
Clin Ther; 2015 Jul; 37(7):1433-42. PubMed ID: 25956353
[TBL] [Abstract][Full Text] [Related]
28. A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study.
Yuan G; Hu C; Zhou Y; Liu J; Huang H; Li Y; Yang D; Zhou F; Zhang YY; Zhou Y
Br J Clin Pharmacol; 2017 Oct; 83(10):2259-2265. PubMed ID: 28511283
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
[TBL] [Abstract][Full Text] [Related]
30. Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study.
Srivastava M; Singh N; Dixit VK; Nath G; Jain AK
Indian J Med Res; 2016 Sep; 144(3):424-432. PubMed ID: 28139541
[TBL] [Abstract][Full Text] [Related]
31. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.
Lim YS; Byun KS; Yoo BC; Kwon SY; Kim YJ; An J; Lee HC; Lee YS
Gut; 2016 May; 65(5):852-60. PubMed ID: 25596179
[TBL] [Abstract][Full Text] [Related]
32. Molecular cloning and phenotypic analysis of drug-resistance mutants with relevant S-region variants of HBV for a patient during 189-month anti-HBV treatment.
Liu Y; Wu C; Chen R; Li X; Xu Z; Li Q; Li L; Wang FS; Yang D; Lu M; Xu D
Antivir Ther; 2019; 24(4):237-246. PubMed ID: 30882363
[TBL] [Abstract][Full Text] [Related]
33. Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures.
Kim YJ; Sinn DH; Gwak GY; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
World J Gastroenterol; 2012 Dec; 18(47):6996-7002. PubMed ID: 23322999
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
[TBL] [Abstract][Full Text] [Related]
35. Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients.
Lee HJ; Kim SJ; Kweon YO; Park SY; Heo J; Woo HY; Hwang JS; Chung WJ; Lee CH; Kim BS; Suh JI; Tak WY; Jang BK
PLoS One; 2018; 13(1):e0190581. PubMed ID: 29329305
[TBL] [Abstract][Full Text] [Related]
36. Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy.
Ha M; Zhang G; Diao S; Lin M; Wu J; Sun L; She H; Shen L; Huang C; Shen W; Huang Z
Intern Med; 2012; 51(12):1509-15. PubMed ID: 22728482
[TBL] [Abstract][Full Text] [Related]
37. Tenofovir monotherapy after achieving complete viral suppression on entecavir plus tenofovir combination therapy.
Kim LH; Chaung KT; Ha NB; Kin KC; Vu VD; Trinh HN; Nguyen HA; Nguyen MH
Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):871-6. PubMed ID: 25919771
[TBL] [Abstract][Full Text] [Related]
38. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
[TBL] [Abstract][Full Text] [Related]
39. Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
Park CH; Jung SW; Shin JW; Bae MA; Lee YI; Park YT; Chung HS; Park NH
Clin Mol Hepatol; 2016 Mar; 22(1):152-9. PubMed ID: 27044766
[TBL] [Abstract][Full Text] [Related]
40. Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.
Suzuki F; Sezaki H; Akuta N; Suzuki Y; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Suzuki Y; Kumada H
Drug Des Devel Ther; 2014; 8():869-73. PubMed ID: 25061278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
